Over a decade of expertise in Health Economics and Market Access, with a specific focus on Infectious Diseases. Currently, as the Value Evidence Lead for GSK Pneumococcal Vaccines, I ensure our portfolio is backed by scientifically credible, high-quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions, and value-based pricing. My role is crucial for aligning Value Evidence generation with the requirements of customers responsible for marketing authorization, recommendations (e.g., NITAGs), and reimbursement, leading to successful patient access, product use, and commercial success.My role involves collaborating with a diverse set of global stakeholders and managing a talented team to develop and execute our evidence strategy, while optimizing resources and ensuring robust outcomes. I deliver critical portfolio materials for informed governance decisions and lead annual budget forecasting.I held various positions in Consulting, both in France and Canada, where I excelled in developing global HE tools like Cost-Effectiveness Models and Budget Impact Analyses. I also successfully coordinated the adaptation of these tools for local markets and led numerous Health Technology Assessment dossier submissions.